

## University of Groningen

### Combining the incompatible

Drooge, Dirk Jan van

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*

2006

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Drooge, D. J. V. (2006). *Combining the incompatible: inulin glass dispersions for fast dissolution, stabilization and formulation of lipophilic drugs*. s.n.

**Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

**Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

## Appendix 1: Bibliography

- 1.) Löbenberg, R. and Amidon, G.L., Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. *Eur. J. Pharm. Biopharm.*, 2000. **50**(1): p. 3-12.
- 2.) Kohri, N., et al., Improving the oral bioavailability of albendazole in rabbits by the solid dispersion technique. *J. Pharm. Pharmacol.*, 1999. **51**(2): p. 159-64.
- 3.) Ali, A.A. and Gorashi, A.S., Absorption and dissolution of nitrofurantoin from different experimental formulations. *Int. J. Pharm.*, 1984. **19**: p. 297-306.
- 4.) Fawaz, F., et al., Bioavailability of norfloxacin from PEG 6000 solid dispersion and cyclodextrin inclusion complexes in rabbits. *Int. J. Pharm.*, 1996. **132**: p. 271-275.
- 5.) El-Zein, H., Riad, L., and El-Bary, A.A., *Enhancement of carbamazepine dissolution: in-vitro and in-vivo evaluation*. *Int. J. Pharm.*, 1998. **168**: p. 209-220.
- 6.) Kai, T., et al., Oral absorption improvement of poorly soluble drug using solid dispersion technique. *Chem. Pharm. Bull. (Tokyo)*, 1996. **44**(3): p. 568-71.
- 7.) Stenberg, P., et al., Prediction of the intestinal absorption of endothelin receptor antagonists using three theoretical methods of increasing complexity. *Pharm. Res.*, 1999. **16**(10): p. 1520-6.
- 8.) Mineo, H., et al., Melibiose, difructose anhydride III and difructose anhydride IV enhance net calcium absorption in rat small and large intestinal epithelium by increasing the passage of tight junctions in vitro. *J. Nutr.*, 2002. **132**(11): p. 3394-9.
- 9.) Watkins, P.B., The barrier function of CYP3A4 and P-glycoprotein in the small bowel. *Adv. Drug Deliv. Rev.*, 1997. **27**: p. 161-170.
- 10.) Dresser, G.K., et al., Fruit juices inhibit organic anion transporting-mediated drug uptake to decrease the oral availability of fexofenadine. *Clin. Pharmacol. Ther.*, 2002. **71**(1): p. 11-20.
- 11.) Ho, P.C., et al., Content of CYP3A4 inhibitors, naringin, naringenin and bergapten in grapefruit and grapefruit juice products. *Pharm. Acta Helv.*, 2000. **74**: p. 379-385.

- 12.) Curatolo, W., Physical chemical properties of oral drug candidates in the discovery and exploratory development settings. *Pharm. Sci. Tech. Today*, 1998. **1**(9): p. 387-393.
- 13.) Lipinski, C.A., et al., Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv. Drug Deliv. Rev.*, 2001. **23**: p. 3-25.
- 14.) Ludden, T.M., *Nonlinear pharmacokinetics: clinical Implications*. *Clin. Pharmacokin.*, 1991. **20**(6): p. 429-46.
- 15.) Tsao, C., et al., Pharmacokinetics of recombinant human superoxide dismutase in healthy volunteers. *Clin. Pharmacol. Ther.*, 1991. **50**(6): p. 713-20.
- 16.) Hidalgo, I.J. and Li, J., *Carrier-mediated transport and efflux in Caco-2 cells*. *Adv. Drug Deliv. Rev.*, 1996. **22**: p. 53-66.
- 17.) Bayomi, M.A., Abanumay, K.A., and Al-Angary, A.A., *Effect of inclusion complexation with cyclodextrins on photostability of nifedipine in solid state*. *Int. J. Pharm.*, 2002. **243**(1-2): p. 107-17.
- 18.) Erlich, L., et al., Relative bioavailability of danazol in dogs from liquid-filled hard gelatin capsules. *Int. J. Pharm.*, 1999. **179**(1): p. 49-53.
- 19.) Torchilin, V.P., Structure and design of polymeric surfactant-based drug delivery systems. *J. Controlled Release*, 2001. **73**(2-3): p. 137-72.
- 20.) Pouton, C.W., Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. *Eur. J. Pharm. Sci.*, 2000. **11 Suppl 2**: p. S93-8.
- 21.) de Boer, A.H., Molema, G., and Frijlink, H.W., *Pulmonary drug delivery: delivery to and through the lung*, in *Drug targeting, organ specific strategies*, G. Molema and D.F.K. Meijer, Editors. 2001, Wiley-VCH: Weinheim (Germany). p. 53-87.
- 22.) Grotenhermen, F., *Pharmacokinetics and pharmacodynamics of cannabinoids*. *Clin. Pharmacokin.*, 2003. **42**(4): p. 327-60.
- 23.) Doyle, E. and Spence, A.A., *Cannabis as a medicine?* *Br. J. Anaesth.*, 1995. **74**(4): p. 359-61.
- 24.) Constantinides, P.P., Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. *Pharm. Res.*, 1995. **12**(11): p. 1561-72.
- 25.) Pouton, C.W., *Formulation of self-emulsifying drug delivery systems*. *Adv. Drug Deliv. Rev.*, 1997. **25**: p. 47-58.
- 26.) Kovarik, J.M., et al., Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. *J. Pharm. Sci.*, 1994. **83**(3): p. 444-6.

- 27.) Noyes, A.A. and Whitney, W.R., *The rate of solution of solid substances in their own solutions*. J. of Am. Chem. Soc., 1897. **19**: p. 930-934.
- 28.) Gohel, M.C. and Patel, L.D., Processing of nimesulide-PEG 400-PG-PVP solid dispersions: preparation, characterization, and in vitro dissolution. Drug Dev. Ind. Pharm., 2003. **29**(3): p. 299-310.
- 29.) Kushida, I., Ichikawa, M., and Asakawa, N., Improvement of dissolution and oral absorption of ER-34122, a poorly water-soluble dual 5-lipoxygenase/cyclooxygenase inhibitor with anti-inflammatory activity by preparing solid dispersion. J. Pharm. Sci., 2002. **91**(1): p. 258-66.
- 30.) Torrado, S., et al., Preparation, dissolution and characterisation of albendazole solid dispersions. Int. J. Pharm., 1996. **140**: p. 247-250.
- 31.) Chiou, W.L. and Riegelman, S., *Pharmaceutical applications of solid dispersion systems*. J. Pharm. Sci., 1971. **60**(9): p. 1281-302.
- 32.) Craig, D.Q.M., The mechanisms of drug release from solid dispersions in water-soluble polymers. Int. J. Pharm., 2002. **231**(2): p. 131-44.
- 33.) Kaushal, A.M., Gupta, P., and Bansal, A.K., *Amorphous drug delivery systems: molecular aspects, design, and performance*. Crit. Rev. Ther. Drug Carrier Syst., 2004. **21**(3): p. 133-93.
- 34.) Hancock, B.C. and Parks, M., *What is the true solubility advantage for amorphous pharmaceuticals?* Pharm. Res., 2000. **17**(4): p. 397-404.
- 35.) Sekiguchi, K. and Obi, N., Studies on Absorption of Eutectic Mixture. I. A comparison of the behaviour of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem. Pharm. Bull., 1961. **9**: p. 866-872.
- 36.) Mullins, J.D. and Macek, T.J., *Some pharmaceutical properties of novobiocin*. J. Am. Pharm. Assoc. Sci. Ed., 1960. **49**: p. 245-8.
- 37.) Breitenbach, J., *Melt extrusion: from process to drug delivery technology*. Eur. J. Pharm. Biopharm., 2002. **54**(2): p. 107-17.
- 38.) Goldberg, A.H., Gibaldi, M., and Kanig, J.L., Increasing dissolution rates and gastrointestinal absorption of drugs via solid solutions and eutectic mixtures. I. Theoretical considerations and discussion of the literature. J. Pharm. Sci., 1965. **54**(8): p. 1145-8.
- 39.) Wilcox, W.R., Friedenber, R., and Back, N., *Zone melting of organic compounds*. Chem. Rev., 1964. **64**: p. 187-220.
- 40.) Rastogi, R.P. and Rama Varma, K.T., *Solid-liquid equilibria in solutions of non-electrolytes*. J. Chem. Soc., 1956. **2**: p. 2097-2101.
- 41.) Chiou, W.L. and Riegelman, S., Preparation and dissolution characteristics of several fast-release solid dispersions of griseofulvin. J. Pharm. Sci., 1969. **58**(12): p. 1505-10.

- 42.) Parks, G.S., Snyder, L.J., and Cattoir, F.R., Studies on glass. XI. Some thermodynamic relations of glassy and alfa-crystalline glucose. *J. Chem. Phys.*, 1934. **2**: p. 595-598.
- 43.) Sarkari, M., et al., Enhanced drug dissolution using evaporative precipitation into aqueous solution. *Int. J. Pharm.*, 2002. **243**(1-2): p. 17-31.
- 44.) Simonelli, A.P., Mehta, S.C., and Higuchi, W.I., *Dissolution rates of high energy polyvinylpyrrolidone (PVP)-sulfathiazole coprecipitates*. *J. Pharm. Sci.*, 1969. **58**(5): p. 538-49.
- 45.) Singh, P., et al., Effect of inert tablet ingredients on drug absorption. I. Effect of polyethylene glycol 4000 on the intestinal absorption of four barbiturates. *J. Pharm. Sci.*, 1966. **55**(1): p. 63-8.
- 46.) Hahn, L. and Sucker, H., *Solid surfactant solutions of active ingredients in sugar esters*. *Pharm. Res.*, 1989. **6**(11): p. 958-60.
- 47.) Lloyd, G.R., Craig, D.Q., and Smith, A., An investigation into the melting behavior of binary mixes and solid dispersions of paracetamol and PEG 4000. *J. Pharm. Sci.*, 1997. **86**(9): p. 991-6.
- 48.) Craig, D.Q.M. and Newton, J.M., Characterisation of polyethylene glycol solid dispersions using differential scanning calorimetry and solution calorimetry. *Int. J. Pharm.*, 1991. **76**: p. 17-24.
- 49.) Sertsou, G., et al., Factors affecting incorporation of drug into solid solution with HPMCP during solvent change co-precipitation. *Int. J. Pharm.*, 2002. **245**(1-2): p. 99-108.
- 50.) Paradkar, A., et al., Characterization of curcumin-PVP solid dispersion obtained by spray drying. *Int. J. Pharm.*, 2004. **271**(1-2): p. 281-6.
- 51.) Forster, A., Hempenstall, J., and Rades, T., Characterization of glass solutions of poorly water-soluble drugs produced by melt extrusion with hydrophilic amorphous polymers. *J. Pharm. Pharmacol.*, 2001. **53**(3): p. 303-15.
- 52.) Bugay, D.E., *Characterization of the solid-state: spectroscopic techniques*. *Adv. Drug Deliv. Rev.*, 2001. **48**(1): p. 43-65.
- 53.) Taylor, L.S. and Zografi, G., *The quantitative analysis of crystallinity using FT-Raman spectroscopy*. *Pharm. Res.*, 1998. **15**(5): p. 755-61.
- 54.) Broman, E., Khoo, C., and Taylor, L.S., A comparison of alternative polymer excipients and processing methods for making solid dispersions of a poorly water soluble drug. *Int. J. Pharm.*, 2001. **222**(1): p. 139-51.
- 55.) Buckton, G. and Darcy, P., The use of gravimetric studies to assess the degree of crystallinity of predominantly crystalline powders. *Int. J. Pharm.*, 1995. **123**: p. 265-271.

- 56.) Burnett, D.J., Thielmann, F., and Booth, J., *Determining the critical relative humidity for moisture-induced phase transitions*. Int. J. Pharm., 2004. **287**(1-2): p. 123-33.
- 57.) Crowley, K.J. and Zografi, G., Water vapor absorption into amorphous hydrophobic drug/poly(vinylpyrrolidone) dispersions. J. Pharm. Sci., 2002. **91**(10): p. 2150-65.
- 58.) Wang, W., Lyophilization and development of solid protein pharmaceuticals. Int. J. Pharm., 2000. **203**: p. 1-60.
- 59.) Sebhatu, T., Angberg, M., and Ahlneck, C., Assessment of the degree of disorder in crystalline solids by isothermal microcalorimetry. Int. J. Pharm., 1994. **104**: p. 135-144.
- 60.) Pikal, M.J., et al., Quantitative crystallinity determinations for beta-lactam antibiotics by solution calorimetry: correlations with stability. J. Pharm. Sci., 1978. **67**(6): p. 767-73.
- 61.) Mosharraf, M., Sebhatu, T., and Nystrom, C., The effects of disordered structure on the solubility and dissolution rates of some hydrophilic, sparingly soluble drugs. Int. J. Pharm., 1999. **177**(1): p. 29-51.
- 62.) Kerc, J. and Srcic, S., *Thermal analysis of glassy pharmaceuticals*. Thermochim. Acta, 1995. **248**: p. 81-95.
- 63.) Breitenbach, J., Schrof, W., and Neumann, J., Confocal Raman-spectroscopy: analytical approach to solid dispersions and mapping of drugs. Pharm. Res., 1999. **16**(7): p. 1109-13.
- 64.) Li, J., Guo, Y., and Zografi, G., The solid-state stability of amorphous quinapril in the presence of beta-cyclodextrins. J. Pharm. Sci., 2002. **91**(1): p. 229-43.
- 65.) Rogers, T.L., et al., A novel particle engineering technology to enhance dissolution of poorly water soluble drugs: spray-freezing into liquid. Eur. J. Pharm. Biopharm., 2002. **54**(3): p. 271-80.
- 66.) Six, K., et al., Increased physical stability and improved dissolution properties of itraconazole, a class II drug, by solid dispersions that combine fast- and slow-dissolving polymers. J. Pharm. Sci., 2004. **93**(1): p. 124-31.
- 67.) De Meuter, P., Rahier, H., and Van Mele, B., The use of modulated temperature differential scanning calorimetry for the characterisation of food systems. Int. J. Pharm., 1999. **192**(1): p. 77-84.
- 68.) Cilurzo, F., et al., *Characterization of nifedipine solid dispersions*. Int. J. Pharm., 2002. **242**(1-2): p. 313-7.
- 69.) Vasanthavada, M., et al., Phase behavior of amorphous molecular dispersions I: Determination of the degree and mechanism of solid solubility. Pharm. Res., 2004. **21**(9): p. 1598-606.

- 70.) Guinot, S. and Leveiller, F., The use of MTDSC to assess the amorphous phase content of a micronized drug substance. *Int. J. Pharm.*, 1999. **192**(1): p. 63-75.
- 71.) Lin, C.-W. and Cham, T.-M., Effect of particle size on the available surface area of nifedipine from nifedipine-polyethylene glycol 6000 solid dispersions. *Int. J. Pharm.*, 1996. **127**: p. 261-272.
- 72.) Sjökvist Saers, E. and Craig, D.Q.M., An investigation into the mechanisms of dissolution of alkyl p-aminobenzoates from polyethylene glycol solid dispersions. *Int. J. Pharm.*, 1992. **83**: p. 211-219.
- 73.) Doherty, C. and York, P., The in-vitro pH-dissolution dependence and in-vivo bioavailability of frusemide-PVP solid dispersions. *J. Pharm. Pharmacol.*, 1989. **41**(2): p. 73-8.
- 74.) Moneghini, M., et al., *Studies in dissolution enhancement of atenolol. Part I.* *Int. J. Pharm.*, 1998. **175**: p. 177-183.
- 75.) Zingone, G. and Rubessa, F., Release of carbamazepine from solid dispersions with polyvinylpyrrolidone/vinylacetate copolymer (PVP/PA). *S.T.P. Pharma Sci*, 1994. **4**(2): p. 122-127.
- 76.) Nernst, W., *Theorie der Reaktionsgeschwindigkeit in heterogenen Systemen.* *Zeitschrift f. Physik. Chem.*, 1904. **47**: p. 52-102.
- 77.) Rasenack, N., Hartenhauer, H., and Müller, B.W., *Microcrystals for dissolution rate enhancement of poorly water-soluble drugs.* *Int. J. Pharm.*, 2003. **254**: p. 137-145.
- 78.) Nelson, E., Solution rate of theophylline salts and effects from oral administration. *J. Am. Pharm. Assoc. Sci. Ed.*, 1957. **46**: p. 607-614.
- 79.) Shaw, D.J., Surface and interfacial tensions, in *Introduction to Colloid & Surface Chemistry.* 1992, Butterworth-Heinemann: Oxford. p. 67-69.
- 80.) Hancock, B.C. and Zografi, G., Characteristics and significance of the amorphous state in pharmaceutical systems. *J. Pharm. Sci.*, 1997. **86**(1): p. 1-12.
- 81.) Corrigan, O.I., Holohan, E.M., and Sabra, K., *Amorphous forms of thiazide diuretics prepared by spray-drying.* *Int. J. Pharm.*, 1984. **18**: p. 195-200.
- 82.) Higuchi, W.I., Mir, N.A., and Desai, S.J., *Dissolution rates of polyphase mixtures.* *J. Pharm. Sci.*, 1965. **54**(10): p. 1405-10.
- 83.) Serajuddin, A.T., Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. *J. Pharm. Sci.*, 1999. **88**(10): p. 1058-66.
- 84.) Corrigan, O.I., *Mechanisms of dissolution of fast release solid dispersions.* *Drug Dev. Ind. Pharm.*, 1985. **11**(2&3): p. 697-724.

- 85.) Langer, M., Urbanetz, N.A., and Lippold, B.C. Supersaturation of carbamazepine released from glassy isomalt tablets. in 4th World Meeting ADRITELF/APGI/APV. 2002. Florence.
- 86.) Weuts, I., et al., Study of the physicochemical properties and stability of solid dispersions of loperamide and PEG6000 prepared by spray drying. Eur. J. Pharm. Biopharm., 2005. **59**(1): p. 119-26.
- 87.) Young, R.J. and Lovell, P.A., *Introduction to polymers*, ed. C. Hall. Vol. Second Edition. 2000, Cheltenham: Stanley Thornes (Publishers) Ltd.
- 88.) Hodge, I.M., *Enthalpy relaxation and recovery in amorphous materials*. J. of Non-Cryst. Solids, 1994. **169**: p. 211-266.
- 89.) Slade, L. and Levine, H., A food polymer science approach to structure-property relationships in aqueous food systems: non-equilibrium behavior of carbohydrate-water systems, in Water relationships in food, H. Levine and L. Slade, Editors. 1991, Plenum Press: New York. p. 29-101.
- 90.) Six, K., et al., Characterization of glassy itraconazole: a comparative study of its molecular mobility below T(g) with that of structural analogues using MTDSC. Int. J. Pharm., 2001. **213**(1-2): p. 163-73.
- 91.) Hancock, B.C., *Disordered drug delivery: destiny, dynamics and the Deborah number*. J. of Pharmacy & Pharmacology, 2002. **54**: p. 737-746.
- 92.) Angell, C.A., Relaxation in liquids, polymers and plastic crystals - strong/fragile pattern and problems. J. of Non-Crystalline Solids, 1991. **131-133**: p. 13-31.
- 93.) Williams, L., Landal, R.F., and Ferry, J.D., Temperature dependance of relaxation mechanisms in amorphous polymers and other glass forming liquids. J. Am. Chem. Soc., 1955. **77**: p. 3701.
- 94.) Crowley, K.J. and Zografi, G., *The use of thermal methods for predicting glass-former fragility*. Thermochim. Acta, 2001. **380**: p. 79-93.
- 95.) Slade, L. and Levine, H., *Non-equilibrium behavior of small carbohydrate-water systems*. Pure Appl. Chem., 1988. **60**: p. 1841-1864.
- 96.) Hancock, B.C., Shamblin, S.L., and Zografi, G., Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm. Res., 1995. **12**: p. 799-806.
- 97.) Kauzmann, W., The nature of the glassy state and the behaviour of liquids at low temperatures. Chem. Rev., 1948. **43**: p. 219-256.
- 98.) Cassel, R.B., DSC method to determine the Kauzmann Temperature, The Temperature of Zero Mobility in Amorphous Systems, TA Instruments: New Castle.
- 99.) Fukuoka, E., Makita, M., and Yamamura, S., Glassy state of Pharmaceuticals. III. Thermal properties and stability of glassy



- pharmaceuticals and their binary glass systems. *Chem. Pharm. Bull.*, 1989. **37**(4): p. 1047-1050.
- 100.) Gordon, M. and Taylor, J.S., Ideal copolymers and the second-order transitions of synthetic rubbers. I. non-crystalline copolymers. *J. Appl. Chem.*, 1952. **2**: p. 493-500.
- 101.) Simha, R. and Boyer, R.F., General relation involving the glass transition temperature and coefficient of expansion of polymers. *J. Chem. Phys.*, 1962. **37**: p. 1003.
- 102.) Ten Brinke, G., Karasz, F.E., and Ellis, T.S., *Depression of glass transition temperatures of polymer networks by diluents*. *Macromolecules*, 1983. **16**: p. 244-249.
- 103.) Lechuga-Ballesteros, D., et al., Properties and stability of a liquid crystal form of cyclosporine-the first reported naturally occurring peptide that exists as a thermotropic liquid crystal. *J. Pharm. Sci.*, 2003. **92**(9): p. 1821-31.
- 104.) Mechoulam, R. and Gaoni, Y., Hashish. IV. The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids. *Tetrahedron*, 1965. **21**(5): p. 1223-9.
- 105.) Fox, G.T. and Flory, P.J., Second-order transitions temperatures and related properties of polystyrene I. Influence of molecular weight. *J. Appl. Physics*, 1950. **21**: p. 581-591.
- 106.) Sekikawa, H., Nakano, M., and Arita, T., *Inhibitory effect of polyvinylpyrrolidone on the crystallization of drugs*. *Chem. Pharm. Bull.*, 1978. **26**(1): p. 118-126.
- 107.) Maa, Y.F., et al., Influenza vaccine powder formulation development: spray-freeze-drying and stability evaluation. *J. Pharm. Sci.*, 2004. **93**(7): p. 1912-23.
- 108.) Matsumoto, T. and Zografi, G., Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinyl-acetate) in relation to indomethacin crystallization. *Pharm. Res.*, 1999. **16**(11): p. 1722-8.
- 109.) Thakkar, A.L., Hirsch, C.A., and Page, J.G., Solid dispersion approach for overcoming bioavailability problems due to polymorphism of nabilone, a cannabinoid derivative. *J. Pharm. Pharmacol.*, 1977. **29**(12): p. 783-4.
- 110.) Eriksson, J.H.C., et al., Investigations into the stabilization of drugs by sugar glasses: III. The influence of various high-pH buffers. *Pharm. Res.*, 2003. **20**(9): p. 1437-43.
- 111.) Khougaz, K. and Clas, S.-D., Crystallization inhibition in solid dispersions of MK-0591 and poly(vinylpyrrolidone) polymers. *J. Pharm. Sci.*, 2000. **89**(10): p. 1325-1334.

- 112.) Miller, D.P., Anderson, R.E., and J.J. Pablo, d., Stabilization of lactate dehydrogenase following freeze-thawing and vacuum-drying in the presence of trehalose and borate. *Pharm. res.*, 1998. **15**: p. 1215-1221.
- 113.) Van den Mooter, G., et al., Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. *Eur. J. Pharm. Sci.*, 2001. **12**(3): p. 261-9.
- 114.) Greenhalgh, D.J., et al., *Solubility parameters as predictors of miscibility in solid dispersions*. *J. Pharm. Sci.*, 1999. **88**(11): p. 1182-90.
- 115.) Timko, R.J. and Lordi, N.G., *Thermal analysis studies of glass dispersion systems*. *Drug Dev. Ind. Pharm.*, 1984. **10**(3): p. 425-451.
- 116.) Damian, F., et al., Physical stability of solid dispersions of the antiviral agent UC-781 with PEG 6000, Gelucire 44/14 and PVP K30. *Int. J. Pharm.*, 2002. **244**(1-2): p. 87-98.
- 117.) Vippagunta, S.R., et al., *Solid-state characterization of nifedipine solid dispersions*. *Int. J. Pharm.*, 2002. **236**(1-2): p. 111-23.
- 118.) Save, T. and Venkitachalam, P., *Studies on solid dispersions of nifedipine*. *Drug Dev. Ind. Pharm.*, 1992. **18**(15): p. 1663-1679.
- 119.) McGinity, J.W., Maincent, P., and Steinfink, H., *Crystallinity and dissolution rate of tolbutamide solid dispersions prepared by the melt method*. *J. Pharm. Sci.*, 1984. **73**(10): p. 1441-4.
- 120.) Allen, L.V.J., Yanchick, V.A., and Maness, D.D., *Dissolution rates of corticosteroids utilizing sugar glass dispersions*. *J. Pharm. Sci.*, 1977. **66**(4): p. 494-496.
- 121.) Forster, A., et al., The potential of small-scale fusion experiments and the Gordon-Taylor equation to predict the suitability of drug/polymer blends for melt extrusion. *Drug Dev. Ind. Pharm.*, 2001. **27**(6): p. 549-60.
- 122.) Langer, M., et al., Investigations on the predictability of the formation of glassy solid solutions of drugs in sugar alcohols. *Int. J. Pharm.*, 2003. **252**(1-2): p. 167-79.
- 123.) Forster, A., et al., Selection of excipients for melt extrusion with two poorly water-soluble drugs by solubility parameter calculation and thermal analysis. *Int. J. Pharm.*, 2001. **226**(1-2): p. 147-61.
- 124.) Hernandez-Trejo, N., et al. Enhancement of the in vitro dissolution rate of the lipophilic drug buparvaquone by incorporation into solid dispersions. in *PharmSci. Fair. 2005. Nice, France*.
- 125.) Vaugelade, C., et al., *Progesterone freeze-dried systems in sublingual dosage form*. *Int. J. Pharm.*, 2001. **229**(1-2): p. 67-73.
- 126.) Orienti, I., et al., Polyvinylalcohol substituted with triethyleneglycolmonoethylether as a new material for preparation of solid

- dispersions of hydrophobic drugs. *Eur. J. Pharm. Biopharm.*, 2002. **54**(2): p. 229-33.
- 127.) Betageri, G.V. and Makarla, K.R., Enhancement of dissolution of glyburide by solid dispersion and lyophilization techniques. *Int. J. Pharm.*, 1995. **126**: p. 155-160.
- 128.) Note for guidance on impurities: residual solvents (CPMP/ICH/283/95), in The European Agency for the Evaluation of Medicinal Products. 1998, EMEA: London. p. 1-18.
- 129.) Eriksson, H.J.C., et al., Investigations into the stabilisation of drugs by sugar glasses: I. Tablets prepared from stabilised alkaline phosphatase. *Int. J. Pharm.*, 2002. **249**(1-2): p. 59-70.
- 130.) Sethia, S. and Squillante, E., *Solid dispersions: revival with greater possibilities and applications in oral drug delivery*. *Crit. Rev. Ther. Drug Carrier Syst.*, 2003. **20**(2-3): p. 215-47.
- 131.) Yoo, S.D., et al., Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles. *Drug Dev. Ind. Pharm.*, 2000. **26**(1): p. 27-34.
- 132.) Teagarden, D.L. and Baker, D.S., *Practical aspects of lyophilization using non-aqueous co-solvent systems*. *Eur. J. Pharm. Sci.*, 2002. **15**(2): p. 115-33.
- 133.) Costantino, H.R., et al., Protein spray freeze drying. 2. Effect of formulation variables on particle size and stability. *J. Pharm. Sci.*, 2002. **91**(2): p. 388-95.
- 134.) Hu, J., Johnston, K.P., and Williams, R.O., 3rd, *Rapid dissolving high potency danazol powders produced by spray freezing into liquid process*. *Int. J. Pharm.*, 2004. **271**(1-2): p. 145-54.
- 135.) Leuenberger, H., *Spray freeze-drying - the process of choice for low water soluble drugs?* *J. of Nanoparticle research*, 2002. **4**: p. 111-119.
- 136.) Maa, Y.F., et al., Protein inhalation powders: spray drying vs spray freeze drying. *Pharm. Res.*, 1999. **16**(2): p. 249-254.
- 137.) Maa, Y.F., et al., Stabilization of alum-adsorbed vaccine dry powder formulations: mechanism and application. *J. Pharm. Sci.*, 2003. **92**(2): p. 319-32.
- 138.) Kompella, U.B. and Koushik, K., *Preparation of drug delivery systems using supercritical fluid technology*. *Crit. Rev. Ther. Drug Carrier Syst.*, 2001. **18**(2): p. 173-199.
- 139.) Palakodaty, S. and York, P., Phase behavioral effects on particle formation processes using supercritical fluids. *Pharm. Res.*, 1999. **16**(7): p. 976-85.
- 140.) Subramaniam, B., Rajewski, R.A., and Snavely, K., *Pharmaceutical processing with supercritical carbon dioxide*. *J. Pharm. Sci.*, 1997. **86**(8): p. 885-90.

- 141.) Moneghini, M., et al., Processing of carbamazepine-PEG 4000 solid dispersions with supercritical carbon dioxide: preparation, characterisation, and in vitro dissolution. *Int. J. Pharm.*, 2001. **222**(1): p. 129-38.
- 142.) Sethia, S. and Squillante, E., Physicochemical characterization of solid dispersions of carbamazepine formulated by supercritical carbon dioxide and conventional solvent evaporation method. *J. Pharm. Sci.*, 2002. **91**(9): p. 1948-57.
- 143.) Vincent, M.F., Kazarian, S.G., and Eckert, C.A., *Tunable diffusion of D2O in CO2-swollen poly(methyl methacrylate) films*. *AIChE*, 1997. **43**(7): p. 1838-1848.
- 144.) Verreck, G., et al., Preparation and characterization of nanofibers containing amorphous drug dispersions generated by electrostatic spinning. *Pharm. Res.*, 2003. **20**(5): p. 810-7.
- 145.) Leuner, C. and Dressman, J., *Improving drug solubility for oral delivery using solid dispersions*. *Eur. J. Pharm. Biopharm.*, 2000. **50**(1): p. 47-60.
- 146.) Lobenberg, R. and Amidon, G.L., Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. *Eur J Pharm Biopharm*, 2000. **50**(1): p. 3-12.
- 147.) Gershanik, T. and Benita, S., *Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs*. *Eur. J. Pharm. Biopharm.*, 2000. **50**(1): p. 179-88.
- 148.) Juppo, A.M., Boissier, C., and Khoo, C., *Evaluation of solid dispersion particles prepared with SEDS*. *Int. J. Pharm.*, 2003. **250**(2): p. 385-401.
- 149.) Velaga, S.P., Ghaderi, R., and Carlfors, J., Preparation and characterisation of hydrocortisone particles using a supercritical fluids extraction process. *Int. J. Pharm.*, 2002. **231**(2): p. 155-66.
- 150.) Martinez-Oharriz, M.C., et al., *Influence of polyethylene glycol 4000 on the polymorphic forms of diflunisal*. *Eur. J. Pharm. Sci.*, 1999. **8**(2): p. 127-32.
- 151.) Hinrichs, W.L.J., Prinsen, M.G., and Frijlink, H.W., *Inulin glasses for the stabilisation of therapeutic proteins*. *Int. J. Pharm.*, 2001. **215**: p. 163-174.
- 152.) Pabst, G., et al., Pharmacokinetics and bioavailability of three different galenic nifedipine preparations. *Arzneimittelforschung*, 1986. **36**(2): p. 256-60.
- 153.) Nocerino, E., Amato, M., and Izzo, A.A., *Cannabis and cannabinoid receptors*. *Fitoterapia*, 2000. **71 Suppl 1**: p. S6-12.
- 154.) Johnston, A. and Holt, D.W., Generic substitution for cyclosporine: what should we be looking for in new formulations? *Transplant. Proc.*, 1998. **30**(5): p. 1652-1653.

- 155.) Lechuga-Ballesteros, D., Bakri, A., and Miller, D.P., Microcalorimetric measurement of the interactions between water vapor and amorphous pharmaceutical solids. *Pharm. Res.*, 2003. **20**(2): p. 308-18.
- 156.) Mithani, S.D., et al., Estimation of the increase in solubility of drugs as a function of bile salt concentration. *Pharm. Res.*, 1996. **13**(1): p. 163-167.
- 157.) Suzuki, H. and Sunada, H., Mechanistic studies on hydrotropic solubilization of nifedipine in nicotinamide solution. *Chem. Pharm. Bull. (Tokyo)*, 1998. **46**(1): p. 125-30.
- 158.) Ismailos, G., et al., *Unusual solubility behaviour of cyclosporin A in aqueous media*. *J. Pharm. Pharmacol.*, 1991. **43**(4): p. 287-9.
- 159.) Garrett, E.R. and Hunt, C.A., Physicochemical properties, solubility, and protein binding of delta-9-tetrahydrocannabinol. *J. Pharm. Sci.*, 1974. **63**(7): p. 1056-1064.
- 160.) Mazzobre, M.F., et al., Effect of salts on the properties of aqueous sugar systems, in relation to biomaterial stabilization. 1. Water sorption behavior and ice crystallization/melting. *Cryobiology*, 2001. **43**(3): p. 199-210.
- 161.) Levine, H. and Slade, L., *Thermomechanical properties of small-carbohydrate-water glasses and 'rubbers'*. *J. Chem. Soc. Faraday Trans. 1*, 1988. **84**(8): p. 2619-2633.
- 162.) Oesterle, J., Franks, F., and Auffret, T., The influence of tertiary butyl alcohol and volatile salts on the sublimation of ice from frozen sucrose solutions: implications for freeze-drying. *Pharm. Dev. Technol.*, 1998. **3**(2): p. 175-83.
- 163.) Saleki-Gerhardt, A. and Zograf, G., Non-isothermal and isothermal crystallization of sucrose from the amorphous state. *Pharm. Res.*, 1994. **11**: p. 1166-1173.
- 164.) Iglesias, H.A., Chirife, J., and Buera, M.P., *Adsorption isotherm of amorphous trehalose*. *J. Sci. Food Agr.*, 1997. **75**: p. 183-186.
- 165.) Flink, J., The retention of volatile components during freeze drying: a structurally based mechanism, in *Freeze drying and advanced food technology*, S.A. Goldblith, L. Rey, and W.W. Rothmayr, Editors. 1975, Academic Press London: London, New York, San Francisco. p. 351-371.
- 166.) Flink, J. and Karel, M., *Mechanism of retention of organic volatiles in freeze-dried systems*. *J. Food Technol.*, 1972. **7**: p. 199-211.
- 167.) Ni, N., et al., Use of pure t-butanol as a solvent for freeze-drying: a case study. *Int. J. Pharm.*, 2001. **226**(1-2): p. 39-46.
- 168.) Thijssen, H.A.C., *Process conditions and retention of volatiles*, in *Freeze drying and advanced food technology*, S.A. Goldblith, L. Rey, and W.W. Rothmayr, Editors. 1975, Academic press London: London, New York, San Francisco. p. 373-400.

- 169.) Flink, J. and Karel, M., *Retention of organic volatiles in freeze-dried solutions of carbohydrates*. J. Agr. Food Chem., 1970. **18**(2): p. 295-297.
- 170.) Flink, J. and Geil-Hansen, F., *Retention of organic volatiles in freeze-dried carbohydrate*. J. Agr. Food Chem., 1972. **20**(3): p. 691-694.
- 171.) Kinoshita, M., et al., Improvement of solubility and oral bioavailability of a poorly water-soluble drug, TAS-301, by its melt-adsorption on a porous calcium silicate. J. Pharm. Sci., 2002. **91**(2): p. 362-70.
- 172.) Craig, D.Q.M. and Newton, J.M., The dissolution of nortriptyline HCl from polyethylene glycol solid dispersions. Int. J. Pharm., 1992. **78**: p. 175-182.
- 173.) Scott, T.A.J. and Melvin, E.H., *Determination of dextran with anthrone*. Analytical Chemistry, 1953. **25**(11): p. 1656-1661.
- 174.) Van Drooge, D.J., Hinrichs, W.L.J., and Frijlink, H.W., Incorporation of lipophilic drugs in sugar glasses by lyophilization using a mixture of water and tertiary butyl alcohol as solvents. J. Pharm. Sci., 2004. **93**(3): p. 713-725.
- 175.) Van Drooge, D.J., et al., Solid Dispersions based on Inulin for the Stabilisation and Formulation of  $\Delta^9$ -Tetrahydrocannabinol. Eur. J. Pharm. Sci., 2004. **21**(4): p. 511-518.
- 176.) Lammert, A.M., Schmidt, S.J., and Day, G.A., *Water activity and solubility of trehalose*. Food Chem., 1998. **61**: p. 139-144.
- 177.) Allen, L.V.J., Levinson, R.S., and Martono, D.D., Dissolution rates of hydrocortisone and prednisone utilizing sugar solid dispersion systems in tablet form. J. Pharm. Sci., 1978. **67**(7): p. 979-981.
- 178.) Sears, E.S., Nyström, C., and Alden, M., Physicochemical aspects of drug release. XVI. The effect of storage on drug dissolution from solid dispersions and the influence of cooling rate and incorporation of surfactant. Int. J. Pharm., 1993. **90**: p. 105-118.
- 179.) Van Drooge, D.J., Hinrichs, W.L.J., and Frijlink, H.W., *Anomalous dissolution behaviour of tablets prepared from sugar glass-based solid dispersions*. J. Controlled Release, 2004. **97**(3): p. 441-452.
- 180.) Van Drooge, D.J., et al., Spray freeze drying to produce a stable  $\Delta^9$ -Tetrahydrocannabinol containing inulin-based solid dispersion powder suitable for inhalation. Eur. J. Pharm. Sci., 2005. **26**(2): p. 231-240.
- 181.) Weuts, I., et al., Phase behaviour analysis of solid dispersions of loperamide and two structurally related compounds with the polymers PVP-K30 and PVP-VA64. Eur. J. Pharm. Sci., 2004. **22**: p. 375-385.
- 182.) Hancock, B.C. and Zografi, G., The relationship between the glass transition temperature and the water content of amorphous pharmaceutical solids. Pharm. Res., 1994. **11**(4): p. 471-7.

- 183.) Six, K., et al., Identification of phase separation in solid dispersions of itraconazole and Eudragit E100 using microthermal analysis. *Pharm. Res.*, 2003. **20**(1): p. 135-8.
- 184.) Tong, P. and Zografi, G., Solid-state characteristics of amorphous sodium indomethacin relative to its free acid. *Pharm. Res.*, 1999. **16**(8): p. 1186-1192.
- 185.) Chan, H.K., Au-Yeung, K.L., and Gonda, I., Development of a mathematical model for the water distribution in freeze-dried solids. *Pharm. Res.*, 1999. **16**(5): p. 660-5.
- 186.) Imamura, K., et al., Water sorption and glass transition behaviors of freeze-dried sucrose-dextran mixtures. *J. Pharm. Sci.*, 2002. **91**(10): p. 2175-81.
- 187.) Lopez-Diez, E.C. and Bone, S., The interaction of trypsin with trehalose: an investigation of protein preservation mechanisms. *Biochem. Biophys. acta*, 2004. **1673**(3): p. 139-48.
- 188.) Van Drooge, D.J., et al., Characterization of the Molecular Distribution of Drugs in Glassy Solid Dispersions at the nano-meter scale, using Differential Scanning Calorimetry and Gravimetric Water Vapour Sorption techniques. *Int. J. Pharm.*, 2006. **310**(1-2): p. 220-229.
- 189.) Gordon, G.W., et al., Quantitative fluorescence resonance energy transfer measurements using fluorescence microscopy. *Biophys. J.*, 1998. **74**(5): p. 2702-13.
- 190.) Jares-Erijman, E.A. and Jovin, T.M., *FRET imaging*. *Nat. Biotechnol.*, 2003. **21**(11): p. 1387-95.
- 191.) Matheyses, A.L., Hoppe, A.D., and Axelrod, D., *Polarized fluorescence resonance energy transfer microscopy*. *Biophys. J.*, 2004. **87**(4): p. 2787-97.
- 192.) Mechoulam, R., Hanus, L., and Fride, E., *Towards cannabinoid drugs--revisited*. *Prog. Med. Chem.*, 1998. **35**: p. 199-243.
- 193.) Fabre, L.F. and McLendon, D., *The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety*. *J. Clin. Pharmacol.*, 1981. **21**(8-9 Suppl): p. 377S-382S.
- 194.) Pertwee, R.G., *Pharmacology of cannabinoid receptor ligands*. *Curr. Med. Chem.*, 1999. **6**(8): p. 635-64.
- 195.) Robson, P., *Cannabis as medicine: time for the phoenix to rise?* *Bmj*, 1998. **316**(7137): p. 1034-5.
- 196.) Garrett, E.R., Gouyette, A.J., and Roseboom, H., *Stability of tetrahydrocannabinols II*. *J. Pharm. Sci.*, 1978. **67**(1): p. 27-32.
- 197.) Mechoulam, R., *Marihuana chemistry*. *Science*, 1970. **168**(936): p. 1159-66.
- 198.) Mechoulam, R. and Hanus, L., *A historical overview of chemical research on cannabinoids*. *Chem. Phys. Lipids*, 2000. **108**(1-2): p. 1-13.

- 199.) Fairbairn, J.W., Liebmann, J.A., and Rowan, M.G., *The stability of cannabis and its preparations on storage*. J. Pharm. Pharmacol., 1976. **28**(1): p. 1-7.
- 200.) Garrett, E.R. and Hunt, C.A., Physicochemical properties, solubility, and protein binding of delta9-tetrahydrocannabinol. J. Pharm. Sci., 1974. **63**(7): p. 1056-64.
- 201.) Eissens, A.C., et al., *Inulin as filler-binder for tablets prepared by direct compaction*. Eur. J. Pharm. Sci., 2002. **15**(1): p. 31-8.
- 202.) Perlin, E., et al., Disposition and bioavailability of various formulations of tetrahydrocannabinol in the rhesus monkey. J. Pharm. Sci., 1985. **74**(2): p. 171-4.
- 203.) Mattes, R.D., et al., *Bypassing the first-pass effect for the therapeutic use of cannabinoids*. Pharmacol. Biochem. Behav., 1993. **44**(3): p. 745-7.
- 204.) Ohlsson, A., et al., Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin. Pharmacol. Ther., 1980. **28**(3): p. 409-16.
- 205.) Elsohly, M.A., et al., Rectal bioavailability of delta-9-tetrahydrocannabinol from the hemisuccinate ester in monkeys. J. Pharm. Sci., 1991. **80**(10): p. 942-5.
- 206.) Elsohly, M.A., et al., *Rectal bioavailability of delta-9-tetrahydrocannabinol from various esters*. Pharmacol. Biochem. Behav., 1991. **40**(3): p. 497-502.
- 207.) Ohlsson, A., et al., Single dose kinetics of deuterium labelled delta 1-tetrahydrocannabinol in heavy and light cannabis users. Biomed. Mass Spectrom., 1982. **9**(1): p. 6-10.
- 208.) Lindgren, J.E., et al., Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis. Psychopharmacology (Berl), 1981. **74**(3): p. 208-12.
- 209.) Davis, K.H., et al., *Some smoking characteristics of marijuana cigarettes*, in *The Cannabinoids: chemical, pharmacologic, and Therapeutic Aspects*, S. Agurell, W.L. Dewey, and R.E. Willette, Editors. 1984, Academic press, Inc.: London. p. 97-109.
- 210.) Naef, M., et al., Development and pharmacokinetic characterization of pulmonary and intravenous delta-9-tetrahydrocannabinol (THC) in humans. J. Pharm. Sci., 2004. **93**(5): p. 1176-84.
- 211.) de Boer, A.H., et al., Dry powder inhalation of antibiotics in cystic fibrosis therapy, part 1: development of a powder formulation with colistin sulfate for a special test inhaler with an air classifier as de-agglomeration principle. Eur. J. Pharm. Biopharm., 2002. **54**(1): p. 17-24.
- 212.) Le Brun, P.P., et al., Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry powder formulation: a



- feasibility study in healthy volunteers and patients. *Eur. J. Pharm. Biopharm.*, 2002. **54**(1): p. 25-32.
- 213.) Maa, Y.F. and Prestrelski, S.J., *Biopharmaceutical powders: particle formation and formulation considerations*. *Curr. Pharm. Biotechnol.*, 2000. **1**(3): p. 283-302.
- 214.) Carrasquillo, K.G., et al., Non-aqueous encapsulation of excipient-stabilized spray-freeze dried BSA into poly(lactide-co-glycolide) microspheres results in release of native protein. *J. Controlled Release*, 2001. **76**(3): p. 199-208.
- 215.) Rogers, T.L., et al., *A novel particle engineering technology: spray-freezing into liquid*. *Int. J. Pharm.*, 2002. **242**(1-2): p. 93-100.
- 216.) de Boer, A.H., et al., Design and application of a new molecular adapter for laser diffraction characterization of inhalation aerosols. *Int. J. Pharm.*, 2002. **249**: p. 233-245.
- 217.) de Boer, A.H., et al., Air classifier technology (ACT) in dry powder inhalation. Part 1. Introduction of a novel force distribution concept (FDC) explaining the performance of a basic air classifier on adhesive mixtures. *Int. J. Pharm.*, 2003. **260**(2): p. 187-200.
- 218.) Brunauer, S., Emmett, P.H., and Teller, E., *Adsorption of gases in multimolecular layers*. *J. Am. Chem. Soc.*, 1938. **60**: p. 309-319.
- 219.) Costantino, H.R., et al., Protein spray-freeze drying. Effect of atomization conditions on particle size and stability. *Pharm. Res.*, 2000. **17**(11): p. 1374-83.
- 220.) Schulz, H., Mechanisms and factors affecting intrapulmonary particle deposition: implications for efficient inhalation therapies. *Pharmaceutical Science & Technology Today*, 1998. **1**(8): p. 336 - 344.
- 221.) Johnson, K.A., *Preparation of peptide and protein powders for inhalation*. *Adv. Drug Del. Rev.*, 1997. **26**: p. 3-15.
- 222.) Hickey, A.J.C., N. M., *Descriptors of irregular particle morphology and powder properties*. *Adv Drug Deliv Rev*, 1997. **26**(1): p. 29-40.